Evidence map›Paper›PMID 32710864›Full record

ArticleThe Lancet. Global health2020

Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study.

Elizabeth C Lee, Dennis L Chao, Joseph C Lemaitre, Laura Matrajt, Damiano Pasetto, Javier Perez-Saez, Flavio Finger, Andrea Rinaldo, Jonathan D Sugimoto, M Elizabeth Halloran and 6 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Mathematical Modeling of Endemic Cholera Transmission.The Journal of infectious diseases · 2021
    Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Elizabeth C LeeDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Dennis L ChaoInstitute for Disease Modeling, Bellevue, WA, USA.
Joseph C LemaitreLaboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Laura MatrajtVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Damiano PasettoLaboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Department of Environmental Sciences, Informatics and Statistics, Ca' Foscari University of Venice, Venice, Italy.
Javier Perez-SaezLaboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Flavio FingerCentre for Mathematical Modelling of Infectious Diseases and Department for Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Andrea RinaldoLaboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Jonathan D SugimotoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M Elizabeth HalloranVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA.
Ira M LonginiDepartment of Biostatistics, College of Public Health and Health Professions, and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
Ralph TernierPartners In Health/Zanmi Lasante, Port-au-Prince, Haiti.
Kenia VissieresPartners In Health/Zanmi Lasante, Port-au-Prince, Haiti.
Andrew S AzmanDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Justin LesslerDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Louise C IversDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Center for Global Health, Massachusetts General Hospital, Boston, MA, USA. Electronic address: LIVERS@mgh.harvard.edu.
École Polytechnique Fédérale de Lausanne · CHJohns Hopkins University · USFred Hutch Cancer Center · USBellevue Hospital Center · USCa' Foscari University of Venice · ITHarvard University · USLondon School of Hygiene & Tropical Medicine · GBUniversity of Florida · USUniversity of Washington · US

Funding

Understanding Transmission with Integrated Genetic and Epidemiologic InferenceU54GM111274 · NIGMS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BEDFORD, TREVOR BC · 2014 to 2018
$12.5M
Immune Responses to Vibrio cholerae infection and vaccination in HaitiR01AI099243 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HARRIS, JASON B, IVERS, LOUISE C. · 2012 to 2022
$7.9M
NIAID NIH HHS R01 AI099243NIGMS NIH HHS U54 GM111274
6 · The paper itself

Abstract

backgroundCholera was introduced into Haiti in 2010. Since then, more than 820 000 cases and nearly 10 000 deaths have been reported. Oral cholera vaccine (OCV) is safe and effective, but has not been seen as a primary tool for cholera elimination due to a limited period of protection and constrained supplies. Regionally, epidemic cholera is contained to the island of Hispaniola, and the lowest numbers of cases since the epidemic began were reported in 2019. Hence, Haiti may represent a unique opportunity to eliminate cholera with OCV.

methodsIn this modelling study, we assessed the probability of elimination, time to elimination, and percentage of cases averted with OCV campaign scenarios in Haiti through simulations from four modelling teams. For a 10-year period from January 19, 2019, to Jan 13, 2029, we compared a no vaccination scenario with five OCV campaign scenarios that differed in geographical scope, coverage, and rollout duration. Teams used weekly department-level reports of suspected cholera cases from the Haiti Ministry of Public Health and Population to calibrate the models and used common vaccine-related assumptions, but other model features were determined independently.

findingsAmong campaigns with the same vaccination coverage (70% fully vaccinated), the median probability of elimination after 5 years was 0-18% for no vaccination, 0-33% for 2-year campaigns focused in the two departments with the highest historical incidence, 0-72% for three-department campaigns, and 35-100% for nationwide campaigns. Two-department campaigns averted a median of 12-58% of infections, three-department campaigns averted 29-80% of infections, and national campaigns averted 58-95% of infections. Extending the national campaign to a 5-year rollout (compared to a 2-year rollout), reduced the probability of elimination to 0-95% and the proportion of cases averted to 37-86%.

interpretationModels suggest that the probability of achieving zero transmission of Vibrio cholerae in Haiti with current methods of control is low, and that bolder action is needed to promote elimination of cholera from the region. Large-scale cholera vaccination campaigns in Haiti would offer the opportunity to synchronise nationwide immunity, providing near-term population protection while improvements to water and sanitation promote long-term cholera elimination.

fundingBill & Melinda Gates Foundation, Global Good Fund, Institute for Disease Modeling, Swiss National Science Foundation, and US National Institutes of Health.

Indexed as

Immunization ProgramsAdministration, OralCholeraCholera VaccinesDisease EradicationHaitiHumansIncidenceModels, BiologicalVaccinationCholera Vaccines

Identifiers

PMID32710864
PMCPMC7738665
OpenAlexW3043936542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.